Dynamic changes in circulating miRNA levels in response to antitumor therapy of lung cancer

Experimental Lung Research

Volumn 42, Issue 2, 2016, Pages 95-102

  Ponomaryova, Anastasia A ^a,c   Morozkin, Evgeny S ^b,d   Rykova, Elena Y ^b,f   Zaporozhchenko, Ivan A ^b,d   Skvortsova, Tatyana E ^b   Dobrodeev, Alexey Y ^a   Zavyalov, Alexander A ^a   Tuzikov, Sergey A ^a   Vlassov, Valentin V ^b   Cherdyntseva, Nadezhda V ^a,e   Laktionov, Pavel P ^b,d   Choinzonov, Evgeny L ^a  

^a CANCER RESEARCH INSTITUTE   (Russian Federation)

^b INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

^c NATIONAL RESEARCH TOMSK POLYTECHNIC UNIVERSITY   (Russian Federation)

^d MESHALKIN NATIONAL MEDICAL RESEARCH CENTER   (Russian Federation)

^e TOMSK STATE UNIVERSITY   (Russian Federation)

^f NOVOSIBIRSK STATE TECHNICAL UNIVERSITY   (Russian Federation)

Author keywords

blood plasma; cell free miRNA; combined antitumor therapy; lung cancer; non invasive diagnostics; therapy response

Indexed keywords

CARBOPLATIN; MICRORNA; MICRORNA 125B; MICRORNA 126; MICRORNA 16; MICRORNA 19B; MICRORNA 205; MICRORNA 25; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; LUNG CANCER; MALE; MICRORNA BLOOD LEVEL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED;

EID: 84961215690     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2016.1155245     Document Type: Article

References (40)

1. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306-13
2. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8
3. Vlassov VV, Laktionov PP, Rykova EY. Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med 2010; 10: 142-65
4. Carethers JM. Proteomics, genomics, and molecular biology in the personalized treatment of colorectal cancer. J Gastrointest Surg 2012; 16: 1648-1650
5. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating microRNA expression profiles in early stage non-small-cell lung cancer. Int J Cancer 2011; 130: 1378-1386
6. Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol 2012; 41: 1897-1912
7. Feng B, Zhang K, Wang, Chen L. Non-small-cell lung cancer and miRNAs: novel biomarkers and promising tools for treatment. Clin Sci (Lond) 2015; 128: 619-634
8. Wang P, Yang D, Zhang H, Wei X, Ma T, Cheng Z, et al. Early detection of lung cancer in serum by a panel of microRNA biomarkers. Clin Lung Cancer 2015; 16: 313-9.e1
9. Wu C, Cao Y, He Z, He J, Hu C, Duan H, Jiang J. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med 2014; 232: 85-95
10. Boldrini L, Giordano M, Servadio A, Alì G, Cocco A, Lucchi M, et al. Prognostic role of miR-205 in early-stage (T1N0) non-small cell lung cancer. Advances in lung cancer 2014; 3: 45-51
11. Ulivi P, Zoli W. miRNAs as non-invasive biomarkers for lung cancer diagnosis. Molecules 2014; 19: 8220-8237
12. Oom AL, Humphries BA, Yang C. MicroRNAs: novel players in cancer diagnosis and therapies. Biomed Res Int 2014; 2014: 959461
13. Vlassov VV, Rykova EIu, Ponomareva AA, Zaporozhchenko IA, Morozkin ES, Cherdyntseva NV, et al. Circulating microRNAs in lung cancer: prospects for diagnostics, prognosis and prediction of antitumortreatment efficiency. Mol Biol (Mosk) 2015; 49: 55-66
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
15. Zaporozhchenko IA, Morozkin ES, Skvortsova TE, Bryzgunova OE, Bondar AA, Loseva EM, et al. A phenol-free method for isolation of microRNA from biological fluids. Anal Biochem 2015; 479: 43-47
16. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006
17. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010; 127: 118
18. Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer 2013; 8: 388-396
19. Võsa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T. Meta-Analysis of microRNA expression in lung cancer. Int J Cancer 2013; 132: 2884-2893
20. Zandberga E, Kozirovskis V, Abols A, Andrejeva D, Purkalne G, Line A. Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes Chromosomes Cancer 2013; 52: 356-369
21. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-33
22. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, et al. MiR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009; 23: 2839-2849
23. Fan Y, Yin S, Hao Y, Yang J, Zhang H, Sun C, et al. MiR-19b promotes tumor growth and metastasis via targeting TP53. RNA 2014; 20: 765-772
24. Mavrakis KJ, Van Der Meulen J, Wolfe AL, Liu X, Mets E, Taghon T, et al. A cooperative microRNA-Tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet 2011; 43: 673-8
25. Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, et al. Genetic dissection of the miR-1792 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 2009; 23: 2806-11
26. Li J, Long W, Li Q, Zhou Q, Wang Y, Zhou B, et al. Distinct expression profiles of lncRNAs between regressive and mature scars. Cell Physiol Biochem 2015; 35: 663-675
27. Mendell JT. MiRiad roles for the miR-17-92 cluster in development and disease. Cell 2008; 133: 217-222
28. Aushev VN, Zborovskaya IB, Laktionov KK, Girard N, Cros MP, Herceg Z, et al. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One 2013; 8: e78649
29. Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG, et al. Evaluation of dynamic change of serum miR-21 and miR-24 in pre-And post-operative lung carcinoma patients. Med Oncol 2012; 29: 3190-3197
30. Wu N, Lin X, Zhao X, Zheng L, Xiao L, Liu J, et al. MiR-125b acts as an oncogene in glioblastoma cells and inhibits cell apoptosis through p53 and p38MAPK-independent pathways. Br J Cancer 2013; 109: 2853-2863
31. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479-1486
32. He J, Jing Y, Li W, Qian X, Xu Q, Li FS, et al. Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis. Plos One 2013; 8: e56647
33. Sun YM, Lin KY, Chen YQ. Diverse functions of miR-125b family in different cell contexts. J Hematol Oncol 2013; 6: 6
34. Yang T, Chen T, Li Y, Gao L, Zhang S, Wang T, et al. Downregulation of miR-25 modulates non-small cell lung cancer by targeting CDC42. Tumor Biol 2015; 36: 1903-11
35. Xu FX, Su YL, Zhang H, Kong JY, Yu H, Qian BY. Prognostic implications for high expression of miR-25 in lung adenocarcinomas of female non-smokers. Asian Pac J Cancer Prev 2014; 15: 1197-1203
36. Sanfiorenzo C, Ilie MI, Belaid A, Barle F, Mouroux J, Marquette CH, et al. Two Panels of Plasma MicroRNAs as Non-Invasive Biomarkers for Prediction of Recurrence in Resectable NSCLC. PLoS One 2013; 8: e54596
37. Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011; 30: 407-414
38. Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi G RR, Picciotto M, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J. Cell. Physiol 2014; 229: 97-99
39. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 2012; 5: 492-7
40. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011; 108: 3713-3718